May 23, 2023
DELIVER presentations at Heart Failure
The DELIVER team was proud to present at Heart Failure 2023 in Prague, Czech Republic. The following analyses were presented:
Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: A prespecified analysis of the DELIVER trial presented by Toru Kondo
Dapagliflozin and Diuretic Utilization in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction in the DELIVER Trial presented by Safia Chatur
Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial presented by Alexander Peikert
Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with Mildly Reduced or Preserved Ejection Faction: Insights from the DELIVER Trial presented by Safia Chatur
Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF or HFpEF in the DELIVER Trial presented by Alexander Peikert
Cardio-Renal-Metabolic Overlap, Outcomes, and Treatment with Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction presented by John W. Ostrominski
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial presented by John W. Ostrominski
Dapagliflozin in Patients With Heart Failure With and Without Peripheral Artery Disease: A patient-level pooled meta-analysis of DAPA-HF and DELIVER presented by Jawad Haider Butt
Effect of Dapagliflozin on Health Status & Quality-of-Life Across the Spectrum of Ejection Fraction: from the DAPA-HF & DELIVER Trials presented by Ankeet S. Bhatt